MX2020010556A - Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. - Google Patents

Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.

Info

Publication number
MX2020010556A
MX2020010556A MX2020010556A MX2020010556A MX2020010556A MX 2020010556 A MX2020010556 A MX 2020010556A MX 2020010556 A MX2020010556 A MX 2020010556A MX 2020010556 A MX2020010556 A MX 2020010556A MX 2020010556 A MX2020010556 A MX 2020010556A
Authority
MX
Mexico
Prior art keywords
cancer
treatment
fibrosis associated
myeloproliferative neoplasms
kinase inhibitors
Prior art date
Application number
MX2020010556A
Other languages
English (en)
Inventor
Steven L Warner
Jason Marc Foulks
Original Assignee
Sumitomo Pharma Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharma Oncology Inc filed Critical Sumitomo Pharma Oncology Inc
Publication of MX2020010556A publication Critical patent/MX2020010556A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan métodos para el tratamiento de neoplasias mieloproliferativas y/o fibrosis asociadas con cáncer. Los métodos descritos comprenden administrar un inhibidor de cinasa PIM, y opcionalmente un inhibidor de cinasa JAK u otro agente terapéutico, a un mamífero que lo necesite.
MX2020010556A 2018-04-13 2019-04-12 Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer. MX2020010556A (es)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862657563P 2018-04-13 2018-04-13
US201862657540P 2018-04-13 2018-04-13
US201862743469P 2018-10-09 2018-10-09
US201862753025P 2018-10-30 2018-10-30
US201862753023P 2018-10-30 2018-10-30
PCT/US2019/027217 WO2019200254A1 (en) 2018-04-13 2019-04-12 Pim kinase inhibitors for treatment of myeloproliferative neoplasms and fibrosis associated with cancer

Publications (1)

Publication Number Publication Date
MX2020010556A true MX2020010556A (es) 2021-03-02

Family

ID=68164545

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020010556A MX2020010556A (es) 2018-04-13 2019-04-12 Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2023001425A MX2023001425A (es) 2018-04-13 2020-10-06 Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2023001425A MX2023001425A (es) 2018-04-13 2020-10-06 Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.

Country Status (9)

Country Link
US (1) US20210113562A1 (es)
EP (1) EP3773560A4 (es)
JP (2) JP2021521170A (es)
KR (1) KR20200143454A (es)
CN (2) CN117838695A (es)
AU (1) AU2019252793A1 (es)
CA (1) CA3095580A1 (es)
MX (2) MX2020010556A (es)
WO (1) WO2019200254A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3409278T3 (pl) 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
JP2022520361A (ja) 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤

Family Cites Families (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
WO2003095448A1 (en) 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
JP4634367B2 (ja) 2003-02-20 2011-02-16 スミスクライン ビーチャム コーポレーション ピリミジン化合物
CA2538413A1 (en) 2003-09-18 2005-03-24 Novartis Ag 2,4-di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
US7776865B2 (en) 2005-10-06 2010-08-17 Schering Corporation Substituted pyrazolo[1,5-a]pyrimidines as protein kinase inhibitors
CN101421269A (zh) 2006-01-13 2009-04-29 环状药物公司 酪氨酸激酶抑制剂及其用途
SI2526934T1 (sl) 2006-09-22 2016-04-29 Pharmacyclics Llc Inhibitorji Bruton tirozin kinaze
WO2008054827A2 (en) 2006-11-03 2008-05-08 Pharmacyclics, Inc. Bruton's tyrosine kinase activity probe and method of using
CA2667487C (en) 2006-11-06 2017-04-04 Supergen, Inc. Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors
WO2008082839A2 (en) 2006-12-29 2008-07-10 Abbott Laboratories Pim kinase inhibitors as cancer chemotherapeutics
AU2008210266B2 (en) 2007-01-31 2013-09-05 Ym Biosciences Australia Pty Ltd Thiopyrimidine-based compounds and uses thereof
CA2679659C (en) 2007-03-01 2016-01-19 Novartis Ag Pim kinase inhibitors and methods of their use
MX2009009117A (es) 2007-03-01 2009-09-03 Supergen Inc Derivados de pirimidin-2,4-diamina y su uso como inhibidores de la cinasa jak2.
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
EP2561875A3 (en) 2007-03-28 2013-06-12 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
EP2139869A2 (en) 2007-04-13 2010-01-06 SuperGen, Inc. Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
WO2009017954A1 (en) 2007-08-01 2009-02-05 Phenomix Corporation Inhibitors of jak2 kinase
CA2743756A1 (en) 2007-11-15 2009-05-22 Musc Foundation For Research Development Inhibitors of pim protein kinases, compositions, and methods for treating cancer
MX2010006748A (es) 2007-12-19 2010-08-18 Vertex Pharma Pirazolo[1,5-a]pirimidinas utiles como inhibidores de jak2.
US20110028405A1 (en) 2007-12-20 2011-02-03 Richard John Harrison Sulfamides as zap-70 inhibitors
US8168794B2 (en) 2008-03-03 2012-05-01 Novartis Ag Pim kinase inhibitors and methods of their use
UY31679A1 (es) 2008-03-03 2009-09-30 Inhibidores de cinasa pim y metodos para su uso
HUE035029T2 (en) 2008-05-21 2018-03-28 Ariad Pharma Inc Kinase inhibitor phosphorus derivatives
PE20110063A1 (es) 2008-06-20 2011-02-16 Genentech Inc DERIVADOS DE [1, 2, 4]TRIAZOLO[1, 5-a]PIRIDINA COMO INHIBIDORES DE JAK
TWI546290B (zh) 2008-06-27 2016-08-21 賽基艾維洛米斯研究股份有限公司 雜芳基化合物及其用途
FR2933409B1 (fr) 2008-07-03 2010-08-27 Centre Nat Rech Scient NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM
AU2009270856B2 (en) 2008-07-16 2013-07-25 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase for the treatment of solid tumors
CA2732791A1 (en) 2008-08-05 2010-02-11 Targegen, Inc. Methods of treating thalassemia
TWI496779B (zh) 2008-08-19 2015-08-21 Array Biopharma Inc 作為ｐｉｍ激酶抑制劑之***吡啶化合物
WO2010022081A1 (en) 2008-08-19 2010-02-25 Array Biopharma Inc. Triazolopyridine compounds as pim kinase inhibitors
WO2010026121A1 (en) 2008-09-02 2010-03-11 Novartis Ag Bicyclic kinase inhibitors
ME01291A (me) 2008-09-02 2013-06-20 Novartis Ag Derivati prikolinamida kao inhibitori kinaze
WO2010026122A1 (en) 2008-09-02 2010-03-11 Novartis Ag Heterocyclic pim-kinase inhibitors
EP2376491B1 (en) 2008-12-19 2015-03-04 Cephalon, Inc. Pyrrolotriazines as alk and jak2 inhibitors
EP2418943A4 (en) 2009-04-15 2012-08-29 Univ Ohio State Res Found CURCUMIN ANALOGUES AS DOUBLE JAK2 / STAT3 INHIBITORS AND METHODS FOR THE PREPARATION AND USE THEREOF
KR20120044305A (ko) 2009-05-20 2012-05-07 사일린 파마슈티칼스, 인크 카이네이즈 억제제로서의 피라졸로피리미딘 및 관련 헤테로사이클
WO2010148351A1 (en) 2009-06-18 2010-12-23 Cylene Pharmaceuticals, Inc. Rhodanines and related heterocycles as kinase inhibitors
US7718662B1 (en) 2009-10-12 2010-05-18 Pharmacyclics, Inc. Pyrazolo-pyrimidine inhibitors of bruton's tyrosine kinase
EP2332917B1 (en) 2009-11-11 2012-08-01 Sygnis Bioscience GmbH & Co. KG Compounds for PIM kinase inhibition and for treating malignancy
WO2011076519A1 (en) 2009-12-22 2011-06-30 Unilever Nv A process for preparing a tea product
US8563539B2 (en) 2009-12-23 2013-10-22 Jasco Pharmaceuticals, LLC Aminopyrimidine kinase inhibitors
UY33213A (es) 2010-02-18 2011-09-30 Almirall Sa Derivados de pirazol como inhibidores de jak
MX342405B (es) 2010-06-03 2016-09-28 Pharmacyclics Inc El uso de inhibidores de la tirosina quinasa de bruton (btk).
EP2590968A1 (en) 2010-07-06 2013-05-15 Novartis AG Cyclic ether compounds useful as kinase inhibitors
CN103298816A (zh) 2010-12-17 2013-09-11 内尔维阿诺医学科学有限公司 作为激酶抑制剂的取代的吡唑并-喹唑啉衍生物
ES2563152T3 (es) 2011-02-25 2016-03-11 Array Biopharma Inc. Compuestos de triazolopiridina como inhibidores de quinasa PIM
US20120225061A1 (en) 2011-03-04 2012-09-06 Matthew Burger Tetrasubstituted cyclohexyl compounds as kinase inhibitors
US9321756B2 (en) 2011-03-22 2016-04-26 Amgen Inc. Azole compounds as PIM inhibitors
EP2720696B1 (en) * 2011-06-14 2016-05-25 Novartis AG Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm
AU2012273164B2 (en) 2011-06-20 2015-05-28 Incyte Holdings Corporation Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors
BR112014000653A2 (pt) 2011-07-13 2017-02-14 Pharmacyclics Inc inibidores de tirosina quinase de bruton
PL3409278T3 (pl) * 2011-07-21 2021-02-22 Sumitomo Pharma Oncology, Inc. Heterocykliczne inhibitory kinazy białkowej
CN102924444B (zh) 2011-08-11 2015-07-08 上海吉铠医药科技有限公司 Pim激酶抑制剂及其制备方法与在制药中的应用
JP6506555B2 (ja) 2011-10-19 2019-04-24 ファーマサイクリックス エルエルシー ブルトン型チロシンキナーゼ（Ｂｔｋ）阻害剤の使用
US8377946B1 (en) 2011-12-30 2013-02-19 Pharmacyclics, Inc. Pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine compounds as kinase inhibitors
US8501724B1 (en) 2012-01-31 2013-08-06 Pharmacyclics, Inc. Purinone compounds as kinase inhibitors
WO2013173518A1 (en) 2012-05-16 2013-11-21 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase
PE20150194A1 (es) 2012-05-21 2015-02-08 Novartis Ag Novedosas n-piridinil amidas ciclicas sustituidas como inhibidores de quinasa
KR20150015021A (ko) 2012-06-04 2015-02-09 파마시클릭스, 인코포레이티드 브루톤 타이로신 키나아제 저해제의 결정 형태
AU2013293087B2 (en) 2012-07-24 2017-08-31 Pharmacyclics Llc Mutations associated with resistance to inhibitors of Bruton's tyrosine kinase (BTK)
CA2881275C (en) 2012-08-06 2020-10-20 Acea Biosciences Inc. Pyrrolopyrimidine compounds as inhibitors of protein kinases
KR101446742B1 (ko) 2012-08-10 2014-10-01 한국화학연구원 Ｎ2,ｎ4-비스(4-(피페라진-1-일)페닐)피리미딘-2,4-디아민 유도체 또는 이의 약학적으로 허용가능한 염 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
CN102880459A (zh) 2012-08-14 2013-01-16 张涛 基于VisualLisp编程语言下的编译实现方法及***
US9315514B2 (en) 2012-08-27 2016-04-19 Rhodes Technologies 1,3-dioxanomorphides and 1,3-dioxanocodides
WO2014033631A1 (en) 2012-08-31 2014-03-06 Novartis Ag N-(3-pyridyl) biarylamides as kinase inhibitors
AU2013323736A1 (en) 2012-09-26 2015-04-09 Mannkind Corporation Multiple kinase pathway inhibitors
PE20151495A1 (es) 2012-11-15 2015-10-23 Pharmacyclics Inc Compuestos de pirrolopirimidina como inhibidores de quinasas
EP2945939B1 (en) 2013-01-15 2020-03-04 Incyte Holdings Corporation Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
US9145387B2 (en) 2013-02-08 2015-09-29 Celgene Avilomics Research, Inc. ERK inhibitors and uses thereof
WO2014130411A1 (en) 2013-02-22 2014-08-28 Emory University Tgf-beta enhancing compositions for cartilage repair and methods related thereto
US9708326B2 (en) 2013-02-25 2017-07-18 Pharmacyclics Llc Inhibitors of bruton's tyrosine kinase
CN105073115A (zh) 2013-03-14 2015-11-18 药品循环有限责任公司 布鲁顿氏酪氨酸激酶抑制剂和cyp3a4抑制剂的组合
EP2970205B1 (en) 2013-03-14 2019-05-08 Tolero Pharmaceuticals, Inc. Jak2 and alk2 inhibitors and methods for their use
JP6575952B2 (ja) 2013-04-08 2019-09-18 ファーマサイクリックス エルエルシー イブルチニブ併用療法
KR102094011B1 (ko) 2013-06-13 2020-03-26 삼성전자주식회사 전자 장치에서 노이즈를 제거하기 위한 장치 및 방법
US9637487B2 (en) 2013-07-02 2017-05-02 Pharmacyclics Llc Purinone compounds as kinase inhibitors
CA2917936A1 (en) * 2013-08-08 2015-02-12 Novartis Ag Pim kinase inhibitor combinations
MX2016002367A (es) 2013-08-23 2016-10-28 Incyte Corp Compuestos de carboxamida de furo y tienopiridina utiles como inhibidores de cinasas pim.
MA38961A1 (fr) 2013-09-30 2018-05-31 Pharmacyclics Llc Composés 3-phenyl-1h-pyrazolo[3,4-d]pyrimidin-4-ylamine substitués inhibiteurs de la tyrosine kinase de bruton utilisés pour traiter par exemple les maladies auto-immunes, respiratoires et inflammatoires, cancer, mastocytose et osteoporose
RU2016125133A (ru) * 2013-11-27 2018-01-09 Новартис Аг Комбинированная терапия, включающая применение ингибиторов jak, cdk и pim
US20160331754A1 (en) * 2014-01-20 2016-11-17 Gilead Sciences, Inc. Therapies for treating cancers
PL3129021T3 (pl) 2014-04-08 2021-05-31 Incyte Corporation Leczenie nowotworów złośliwych z komórek b za pomocą skojarzenia inhibitora jak i pi3k
TW201545749A (zh) 2014-04-25 2015-12-16 Univ Nat Cheng Kung 樟芝酸ａ、一種ｊａｋ２／３酪胺酸激酶抑制劑及有潛力的肝炎治療劑
WO2016161248A1 (en) * 2015-04-02 2016-10-06 Tolero Pharmaceuticals, Inc. Targeting pim kinases in combination with btk inhibition
CN105919955A (zh) * 2016-06-13 2016-09-07 佛山市腾瑞医药科技有限公司 一种鲁索利替尼制剂及其应用
AU2020205643A1 (en) * 2019-01-09 2021-08-19 Celgene Corporation Antiproliferative compounds and second active agents for use in treating multiple myeloma
JP2022520361A (ja) * 2019-02-12 2022-03-30 スミトモ ダイニッポン ファーマ オンコロジー， インコーポレイテッド 複素環式タンパク質キナーゼ阻害剤を含む製剤
AU2020372334A1 (en) * 2019-10-21 2022-05-05 Celgene Corporation Substituted 4-aminoisoindoline-1,3-dione compounds and second active agents for combined use

Also Published As

Publication number Publication date
MX2023001425A (es) 2023-03-03
US20210113562A1 (en) 2021-04-22
JP2024038485A (ja) 2024-03-19
KR20200143454A (ko) 2020-12-23
CN112236139A (zh) 2021-01-15
JP2021521170A (ja) 2021-08-26
EP3773560A1 (en) 2021-02-17
WO2019200254A1 (en) 2019-10-17
EP3773560A4 (en) 2022-01-19
CN117838695A (zh) 2024-04-09
CA3095580A1 (en) 2019-10-17
AU2019252793A1 (en) 2020-10-15

Similar Documents

Publication Publication Date Title
MX2021004639A (es) Combinaciones de inhibidores de desmetilasa-1 especifica de lisina (lsd1) para uso en el tratamiento de tumores solidos.
MX2019011679A (es) Reemplazo de un pre-acondicionamiento citotoxico antes de una inmunoterapia celular.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
MX2017015574A (es) Inhibidores de tirosina quinasa de bruton.
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
MX2016008201A (es) Tratamiento del cancer usando combinaciones de inhibidores de erk y raf.
TW201613919A (en) Inhibitors of Bruton's tyrosine kinase
MX2018006674A (es) Tratamiento de cancer usando 2-desoxi-2-fluoro-l-fucosa en combinacion con un inhibidor del punto de control.
MX2018001289A (es) Terapias de combinacion para el tratamiento del cancer.
MX2018005544A (es) Uso de agonistas del receptor tipo toll- 8 (tlr8) para tratar cancer.
MX2015014599A (es) Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer.
MX2020001727A (es) Terapia de combinacion.
PH12015502616A1 (en) Pharmaceutical combination comprising metformin and dihydroquercetin and its use for the treatment of cancer
MX2019005779A (es) Metodos para tratar trastornos del desarrollo y/o trastornos convulsivos con flupirtina.
MX2019002108A (es) Terapia de combinacion con inhibidores de glutaminasa.
MX2021002321A (es) Nuevos metodos.
MX2019013862A (es) Terapia de combinacion.
MX2020002889A (es) Un esteroide c21-n-pirazolilo 19-nor c3,3-disustituido, y métodos de uso del mismo.
MX2023001425A (es) Inhibidores de cinasa de insercion proviral en linfomas murinos (pim) para el tratamiento de neoplasias mieloproliferativas y fibrosis asociadas con cancer.
MX2016016388A (es) Uso de compuestos de tienotriazolodiazepina para el tratamiento de cancer de pulmon de celula no pequeña y/o cancer de pulmon de celula pequeña.
ZA201901367B (en) Inhibition of olig2 activity
MX2017015532A (es) Terapia de combinacion pac-1.
MX2022014792A (es) Cocristales, composiciones farmaceuticas de los mismos y metodos de tratamiento que los implican.
MX2019002901A (es) Tratamiento de esclerosis multiple con chs-131.
EA201991175A1 (ru) Применение в медицине интерферона-лямбда для лечения фиброза